Contact information
Research groups
DPhil Supervisor Profile
David Kerr
CBE FMedSci FRCP
Professor of Cancer Medicine
- Consultant Physician
In collaboration with Dr Rachel Midgley, Oncology Clinical Trials Office, we have conducted a series of international adjuvant trials of chemotherapy for colorectal cancer. In parallel, we have established a biorepository of tissue and constitutional DNA (n=3500) which has allowed us to collaborate with Ian Tomlinson to generate a number of cancer susceptibility SNPs and commercial partners to characterise a prognostic mRNA signature which assists in selection of patients for chemotherapy. We are currently developing biomarkers for the anti-angiogenic agent bevacizumab.
Key publications
-
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
Journal article
Kerr RS. et al, (2016), Lancet Oncol, 17, 1543 - 1557
Recent publications
-
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
Journal article
Law PJ. et al, (2019), Nat Commun, 10
-
Confirmation that somatic mutations of beta-2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial.
Journal article
Barrow P. et al, (2019), Histopathology
-
Oxford Textbook of Cancer Biology
Book
Pezzella F. et al, (2019)
-
Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features.
Journal article
Jiang W. et al, (2019), Int J Cancer, 144, 2161 - 2168
-
An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistance.
Journal article
Li N. et al, (2019), Oncogenesis, 8